A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

Conditions

• COVID-19 Vaccines

Eligibility Criteria

Sex

ALL

Age

18 Years - 64 Years

Healthy Volunteers

Accepted

Interventions

• BNT162b2 Vaccine — BIOLOGICAL
  Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.
• Tdap Vaccine — BIOLOGICAL
  Participants will receive a single injection containing Tdap on Day 1.

Study Details

The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough). The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines. Participants will be in the study for about 12 months.

Key Dates

First listed

Jul 28, 2026

Start date

Jul 23, 2026

Status verified

Aug 2026

Primary completion

Aug 20, 2027

Completion

Aug 20, 2027

Study Design

Enrollment

200 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: BNT162b2 Vaccine
  Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.
• Active Comparator: Tdap Vaccine
  Participants will receive a single injection containing Tdap on Day 1.

Primary Outcome Measure

Percentage of participants reporting local reactions or systemic events [ Time Frame: From Day 1 up to 7 days after Vaccination ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (5)

Find similar trials in Walnut Creek, CA